'Thinner Strut' Bioresorbable Scaffold Holds Own vs Mainstay DES medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Randomized clinical trials compare effects of coronary revascularization versus medical therapy alone news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Photo by Getty Images
A new randomized study could reduce the morbidity and mortality associated with COVID-19 and streamline clinical research at Yale. The study will enroll 466 patients across five different Yale New Haven Hospital sites to identify a potential COVID-19 treatment.
Led by Alexandra Lansky, MD, a professor of medicine and director of the Yale Cardiovascular Research Group (YCRG), the COLSTAT clinical trial (Colchicine/Statin for the Prevention of COVID-19 Complications) will combine two widely available medications to reduce complications in infected patients. Both have been in use for decades and have no adverse effects in patients with COVID-19.
December 14, 2020
In a world indelibly changed by COVID-19 more than 72 million confirmed cases and 1.6 million deaths, and counting people and institutions have proven adaptable and resilient: look no further than the development of vaccines and the rollout now underway.
That achievement would not have been possible without improvements and acceleration in the clinical research enterprise, something also seen within cardiology research, which had to respond quickly once it became clear that COVID-19 was affecting not just the lungs, but also the heart and other organs.
This story is part of
Envision Change, an end-of-2020 series imagining a different future for cardiology, medicine, research, and health. SEE ALSO: Funding the Future, Remaking Medicine, Heroes to Human.